Shares of RXi Pharmaceuticals Corp. (NASDAQ:RXII) have received an average broker rating score of 1.00 (Strong Buy) from the two brokers that provide coverage for the company, Zacks Investment Research reports. Two equities research analysts have rated the stock with a strong buy rating.
Analysts have set a 1-year consensus target price of $5.75 for the company and are anticipating that the company will post ($0.34) EPS for the current quarter, according to Zacks. Zacks has also given RXi Pharmaceuticals Corp. an industry rank of 82 out of 265 based on the ratings given to its competitors.
A number of research firms have commented on RXII. Zacks Investment Research lowered shares of RXi Pharmaceuticals Corp. from a “buy” rating to a “hold” rating in a research note on Friday, July 15th. HC Wainwright began coverage on shares of RXi Pharmaceuticals Corp. in a research note on Tuesday, June 7th. They set a “buy” rating and a $3.50 price objective for the company.
RXi Pharmaceuticals Corp. (NASDAQ:RXII) traded down 1.804% during midday trading on Wednesday, reaching $1.905. 1,348 shares of the company’s stock traded hands. The company’s 50-day moving average price is $2.23 and its 200 day moving average price is $2.35. RXi Pharmaceuticals Corp. has a 52 week low of $1.26 and a 52 week high of $6.49. The stock’s market capitalization is $12.49 million.
RXi Pharmaceuticals Corp. (NASDAQ:RXII) last posted its quarterly earnings data on Thursday, August 11th. The biotechnology company reported ($0.34) EPS for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.02. During the same quarter in the previous year, the business earned ($0.50) EPS. On average, equities research analysts expect that RXi Pharmaceuticals Corp. will post ($1.40) earnings per share for the current year.
An institutional investor recently raised its position in RXi Pharmaceuticals Corp. stock. Renaissance Technologies LLC increased its position in RXi Pharmaceuticals Corp. (NASDAQ:RXII) by 22.1% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 950,900 shares of the biotechnology company’s stock after buying an additional 172,100 shares during the period. Renaissance Technologies LLC owned approximately 1.46% of RXi Pharmaceuticals Corp. worth $257,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 11.76% of the company’s stock.
RXi Pharmaceuticals Corp. Company Profile
RXi Pharmaceuticals Corporation is a clinical-stage ribonucleic acid (RNA) interference (RNAi) company developing therapeutics in dermatology and ophthalmology that address unmet medical needs. The Company’s development programs are based on its self-delivering RNAi (sd-rxRNA) platform and Samcyprone, a topical immunomodulator.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for RXi Pharmaceuticals Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RXi Pharmaceuticals Corp. and related companies with MarketBeat.com's FREE daily email newsletter.